Inclusion Criteria:

          -  1. Willing to sign Informed Consent;

          -  2. Part A, must have a histologically or cytologically documented, incurable, or
             metastatic solid tumor that has progressed on, or been intolerant to, all standard
             systemic therapy options for the tumor type in the metastatic setting, or must have a
             tumor type for which no such standard systemic option exists;

          -  3. Part B, must have a histologically or cytologically documented diagnosis of
             esophageal or gastric carcinoma, nasopharyngeal carcinoma (NPC), hepatocellular
             carcinoma (HCC), both soft tissue sarcoma (excluding leiomyosarcoma), chondrosarcoma,
             or with agreement of the sponsor, or other tumors who have received at least one line
             of standard systemic therapy for their respective tumor type in the metastatic setting
             with progressive locally advanced or metastatic disease that is not amenable to
             definitive local therapy with curative intent. Patient with MSI-H/dMMR Tumors are
             eligible to enroll.

               1. Subjects with NPC must have received, or been intolerant to, a platinum-based
                  combination as part of their prior therapy for advanced/metastatic disease;

               2. Subjects with soft tissue sarcoma and chondrosarcoma must have radiographic
                  evidence of progression within the previous 6 months and must have received at
                  least 1 line of systemic therapy;

               3. Subjects with esophageal cancer must have received, or been intolerant to, a
                  platinum-based combination as part of their prior therapy for advanced/metastatic
                  disease;

               4. Subjects with gastric cancer must have received, or been intolerant to, a
                  fluoropyrimidine-platinum combination as part of their prior therapy for
                  advanced/metastatic disease;

               5. Subjects with HCC must have received (or been intolerant to) sorafenib as part of
                  their prior therapy for advanced metastatic disease.

          -  4. Measurable disease per RECIST v1.1 and irRECIST;

          -  5. ECOG performance status of 0 or 1;

          -  6. Adequate organ and marrow function;

          -  7. Willingness to provide consent for biopsy samples;

          -  8. For females of childbearing potential, use effective contraception from time of
             screening though 90 days post last dose of Toripalimab.

        Exclusion Criteria:

          -  1. Concurrent enrollment in another clinical study, unless it is an observational
             (non-interventional) clinical study or the follow-up period of an interventional
             study;

          -  2. Any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic therapy for
             cancer treatment. Concurrent use of hormones for non-cancer related conditions is
             acceptable (e.g., insulin for diabetes & hormone replacement therapy). Local treatment
             of isolated lesions for palliative intent is acceptable;

          -  3. Receipt of any investigational anti-cancer therapy within 4 weeks prior to first
             dose of Toripalimab;

          -  4. Current use or prior use of immunosuppressive medication within 4 weeks prior to
             first dose of Toripalimab, with the exception of intranasal and inhaled
             corticosteroids or systemic corticosteroids not to exceed 10mg/day of prednisone or
             equivalent;

          -  5. Part A: Prior exposure to immunotherapy such as but not limited to other
             anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies excluding vaccines. Part B: Exclusion
             of prior immunotherapy exposure will be limited to anti-PD-1, anti-PD-L1, or
             anti-PD-L2;

          -  6. Prior allogeneic bone marrow transplantation or prior solid organ transplantation;

          -  7. Major surgery within 4 weeks prior to first dose of Toripalimab or still recovering
             from prior surgery;

          -  8. Unresolved toxicities from prior anticancer therapy defined as having not resolved
             to baseline or to Grade 0 or 1, or to levels dictated in the inclusion/exclusion
             criteria with the exception of alopecia;

          -  9. Active or prior documented autoimmune disease within the past 2 years. Subjects
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within
             the past 2 years are not excluded;

          -  10. Known history of tuberculosis;

          -  11. Known to be human immunodeficiency virus (HIV) positive, hepatitis B, or hepatitis
             C positive;

          -  12. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis);

          -  13. History of primary immunodeficiency;

          -  14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure according to NYHA Functional
             Classification ≥3, uncontrolled hypertension, unstable angina pectoris, cardiac
             arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social
             situations that would limit compliance with study requirements, substantially increase
             risk of incurring adverse events from Toripalimab, or compromise the ability of the
             subject to give written informed consent;

          -  15. Symptomatic or untreated central nervous system metastases requiring concurrent
             treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids.
             Subjects with previously treated brain metastases may participate provided they are
             clinically stable for at least 4 weeks prior to study entry, have no evidence of new
             or enlarging metastases, and are off steroids;

          -  16. Receipt of live attenuated vaccination within 30 days prior to study entry or
             within 4 weeks of receiving Toripalimab;

          -  17. Pregnancy or breastfeeding women.